Navigation
Navigation
User login
Back to top
Description of the image

Discussion articles

Click a link below to read our expert contributors' articles and join the discussion

Iron Chelation Therapy

Iron Chelation Therapy for patients with MDS: important or nonsense?

Marlijn Hoeks, MD, PhD internist-hematologist, the Netherlands

29 October 2020

I-CARE for MDS

I-CARE for MDS: Development of Guidelines-Based Indicators

Dr. med. Nicolas Bonadies, Austria

31 October 2019

Canyon between diagnosis and therapy

The canyon between diagnosis and therapy in MDS

Bergit Korschan-Kuhle, MDS patient, Germany

19 June 2019

Finding the right numbers for myelodysplastic syndromes

Finding the right numbers for myelodysplastic syndrome

Inga Mandac Rogulj, MD, Clinical Hospital Merkur, Croatia

5 March 2019

The importance of assessment of quality of life

Assessment of Quality of life should be part of patient care in patients with MDS

Ass. Prof. Reinhard Stauder, Inssbruck Medical University, Austria

18 December 2018

Challenge of providing equal access to care

The challenge of providing equal access to care - will EuroBloodNet make a difference?

Dr. María del mar Manu Pereira, Hospítal Clinic de Barcelona, Spain

14 August 2018

Managing MDS in Eastern Europe: challenges and solutions

Managing MDS in Eastern Europe: challenges and solutions

Prof. Aleksandar Savic, Clinical Centre of Vojvodina, Serbia

28 June 2018

Seed & soil: the challenges of MDS treatment

Seed and soil: the challenges of MDS treatment

Dr. Rena Buckstein, Sunnybrook health sciences centre, Canada

17 May 2018

I'm gonna lay down my burden

I’m gonna lay down my burden …

Bergit Korschan-Kuhle, MDS patient, Germany

28 February 2018

Role of allogeneic stem cell transplantation

The role of allogeneic hematopoietic stem cell transplantation for patients with Myelodysplastic Syndromes

Prof. Theo de Witte, Radboud University Medical Centre, Netherlands

9 January 2018

When should ESA's be started in lower risk MDS?

When should erytropoietic stimulating agents be started in lower-risk MDS?

Prof. Eva Hellström-Lindberg, Karolinska Instituted, Sweden

31 October 2017

Still CARPE DIEM

Still CARPE DIEM - a patients perspective on transfusions

Bergit Korschan-Kuhle, MDS patient, Germany

5 October 2017

Importance of geriatric assessment at diagnosis

Importance of geriatric assessment of MDS patients at diagnosis

Corien Eeltink, nursing specialist hematology, VUmc, Netherlands

31 August 2017

MDS patients speak out

MDS patients speak out

Patrick Festy, Connaitre et combattre les myélosdysplasies (CCM)

11 April 2017

Can MDS specialists review more patients

Can MDS specialists review (and help) more MDS patients please?

Professor David Bowen, Leeds Teaching Hospitals NHS Trust, UK

21 March 2017